article · The Journal of Immunology
Schistosoma mansoni infection affects millions of people globally, typically causing mild symptoms but occasionally leading to severe periportal fibrosis and death. Periportal fibrosis involves excess extracellular matrix deposition driven by chronic inflammation from parasite eggs and antigens, a process regulated by cytokines such as interferon-gamma. An examination of genetic variations in an endemic population revealed two specific polymorphisms in the third intron of the interferon-gamma gene linked to disease outcomes. The variant designated plus 2109 A/G correlates with an increased risk of severe periportal fibrosis, whereas the plus 3810 G/A variant associates with reduced fibrosis. These genetic alterations change how nuclear proteins interact with the intronic DNA, pointing to altered messenger RNA expression. These findings align with earlier evidence linking low interferon-gamma production to disease severity, reinforcing the central role of interferon-gamma signalling in controlling liver pathology.
Most individuals infected with schistosomes develop mild symptoms, but a minority suffer life-threatening liver fibrosis. Identifying specific genetic variations that influence interferon-gamma regulation helps explain why severe disease occurs in certain people. This improves understanding of the host immune response and highlights biological pathways that control tissue damage during chronic parasitic infections in endemic areas.
This work represents early-stage basic genetics research that identifies potential biomarkers for severe fibrosis risk in schistosomiasis patients. Diagnostic developers or clinical researchers could potentially use these genetic markers to develop risk-stratification screening tools in endemic regions. However, the abstract does not describe any ready clinical assays or therapeutic interventions, indicating that substantial development and clinical validation would be required before real-world diagnostic use.
AI-generated from the published abstract. Always read the original work before citing.
Schistosome infection is a major public health concern affecting millions of people living in tropical regions of Africa, Asia, and South America. Schistosomes cause mild clinical symptoms in most subjects, whereas a small proportion of individuals presents severe clinical disease (as periportal fibrosis (PPF)) that may lead to death. Severe PPF results from an abnormal deposition of extracellular matrix proteins in the periportal spaces due to a chronic inflammation triggered by eggs and schistosome Ags. Extracellular matrix protein production is regulated by a number of cytokines, including IFN-gamma. We have now screened putative polymorphic sites within this gene in a population living in an endemic area for Schistosoma mansoni. Two polymorphisms located in the third intron of the IFN-gamma gene are associated with PPF. The IFN-gamma +2109 A/G polymorphism is associated with a higher risk for developing PPF, whereas the IFN-gamma +3810 G/A polymorphism is associated with less PPF. The polymorphisms result in changes in nuclear protein interactions with the intronic regions of the gene, suggesting that they may modify IFN-gamma mRNA expression. These results are consistent with the results of previous studies. Indeed, PPF is controlled by a major locus located on chromosome 6q22-q23, closely linked to the gene encoding the alpha-chain of the IFN-gamma receptor, and low IFN-gamma producers have been shown to have an increased risk of severe PPF. Together, these observations support the view that IFN-gamma expression and subsequent signal transduction play a critical role in the control of PPF in human hepatic schistosome infection (S. mansoni).
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4049/jimmunol.171.10.5596
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.